US FDA’s Dry July? Few Goal Dates Portend Quiet Month For Approvals

 
• By Bridget Silverman

Sun’s deuruxolitinib and Novo Nordisk’s insulin icodec stand out as new molecular entities among the small cluster of US FDA user fee goal dates in July.

dry land
After a busy June, far fewer products have FDA user fee goal dates in July. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers